Health Canada pledges more plant inspections and more transparency

Health Canada, which has been accused of not providing the public with enough info about quality concerns over the drugs sold there, says it will increase the number of plant inspections it will do and put more information online, the Toronto Star reports. "Transparency initiatives related to inspections are a key priority to Health Canada," the regulator said in a a letter last month to drug manufacturers about its plans. The agency has been criticized for not letting the public know about problems with Canada-based Apotex, which has been repeatedly cited by the FDA for manufacturing problems at its plants in Canada and India. Story | More

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.